Tejara Capital Ltd Has $9.62 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Tejara Capital Ltd trimmed its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 42.7% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 813,550 shares of the company’s stock after selling 607,440 shares during the quarter. Roivant Sciences comprises approximately 6.2% of Tejara Capital Ltd’s portfolio, making the stock its 2nd biggest position. Tejara Capital Ltd’s holdings in Roivant Sciences were worth $9,624,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of ROIV. US Bancorp DE grew its stake in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after purchasing an additional 1,948 shares during the period. GAMMA Investing LLC grew its stake in shares of Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after purchasing an additional 1,288 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock valued at $84,000 after purchasing an additional 1,507 shares during the period. Quarry LP grew its stake in shares of Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after purchasing an additional 2,500 shares during the period. Finally, Blue Trust Inc. grew its stake in shares of Roivant Sciences by 550.1% during the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock valued at $91,000 after purchasing an additional 6,667 shares during the period. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Trading Up 1.8 %

Shares of NASDAQ:ROIV opened at $10.85 on Tuesday. The stock has a 50 day moving average of $10.80 and a 200 day moving average of $11.49. The company has a market cap of $7.74 billion, a PE ratio of -72.33 and a beta of 1.26. Roivant Sciences Ltd. has a 12-month low of $9.76 and a 12-month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Equities research analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the sale, the chief accounting officer now directly owns 163,264 shares of the company’s stock, valued at $1,702,843.52. This trade represents a 58.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $11.49, for a total transaction of $1,149,000.00. Following the sale, the chief operating officer now directly owns 595,580 shares of the company’s stock, valued at approximately $6,843,214.20. This trade represents a 14.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,388,170 shares of company stock valued at $27,612,299 in the last three months. 7.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have issued reports on ROIV. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $18.08.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.